一分钟看懂
这是一项关于胆道癌的IV 期研究，登记的药物或干预包括Iparomlimab and Toripalimab；Bevacizumab；Gemcitabine (1000 mg/m2)；Cisplatin，当前状态为招募中。登记地点显示中国武汉有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Iparomlimab and Toripalimab；Bevacizumab；Gemcitabine (1000 mg/m2)；Cisplatin · IV 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology · 武汉
公开的入选条件
- * Informed Consent: Patients voluntarily join this study and sign the informed consent form.
- * Age: 18 to 75 years old, male or female.
- * Histologically or cytologically confirmed, unresectable locally advanced or metastatic biliary tract cancer (BTC), including cholangiocarcinoma (intrahepatic and extrahepatic) and gallbladder carcinoma.
- * No prior systemic anti-tumor therapy for locally advanced or metastatic BTC.
- * At least one measurable lesion according to RECIST v1.1 that is suitable for accurate repeated measurement. Lesions previously irradiated or brain metastases are not eligible as target lesions.
- * Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.
- * Adequate organ function
- * For HBsAg positive subjects: HBV DNA must be \< 2000 IU/mL (or \< 10⁴ copies/mL), and effective antiviral therapy (e.g., Entecavir, Tenofovir, TAF, or Tenofovir Amibufenamide) must be administered throughout the study.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07619235；登记信息更新于 2026-09-15。